Major depressive disorder, recurrent, mild
Methodology & AI Transparency ⓘ
Major depressive disorder, recurrent, mild Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Cataloged under federal diagnostic code F33.0 in Depression & Mood, Major depressive disorder, recurrent, mild requires medication response pharmacogenomics [Major depressive disorder, recurrent, mild F33.0] so specialists can calibrate treatment intensity against TSH & Free in Major depressive disorder, recurrent, mild (F33.0: T4 Rule-Out) benchmarks.
- 2 Real-world patient consensus: Clinical coding for Major depressive disorder, recurrent, mild uses ICD-10 F33.0 across Depression & Mood specialty care.
- 3 Typical cash cost range: Workup highlights for Major depressive disorder, recurrent, mild (F33.0): medication response pharmacogenomics [Major depressive disorder, recurrent, mild F33.0].
- 4 Top reported side effects / signs: Key Depression & Mood biomarkers for Major depressive disorder, recurrent, mild (F33.0): TSH & Free in Major depressive disorder, recurrent, mild (F33.0: T4 Rule-Out) & Serum Vitamin D in Major depressive disorder, recurrent, mild (F33.0: & RBC Folate) (25(OH)D 40 – 65 ng/mL (F33.0)).
Ask our AI Specialists anything about Major depressive disorder, recurrent, mild
What Is Major depressive disorder, recurrent, mild?
Cataloged under federal diagnostic code F33.0 in Depression & Mood, Major depressive disorder, recurrent, mild requires medication response pharmacogenomics [Major depressive disorder, recurrent, mild F33.0] so specialists can calibrate treatment intensity against TSH & Free in Major depressive disorder, recurrent, mild (F33.0: T4 Rule-Out) benchmarks.
Pathophysiology, Underlying Causes & Clinical Presentation
Biological expression of Major depressive disorder, recurrent, mild (F33.0, Depression & Mood) reflects hypothalamic-pituitary-adrenal (HPA) axis in Major depressive disorder, recurrent, mild (F33.0: cortisol hyperactivity). longitudinal control is benchmarked via TSH & Free in Major depressive disorder, recurrent, mild (F33.0: T4 Rule-Out).
Common Symptoms & Clinical Signs
- • Presentation of Major depressive disorder, recurrent, mild (F33.0): slowed concentration, indecisiveness, in Major depressive disorder, recurrent, mild (F33.0: and physical heaviness)
- • Secondary Major depressive disorder, recurrent, mild clinical sign: loss of interest in Major depressive disorder, recurrent, mild (F33.0: or pleasure in)
- • Symptom flares in Major depressive disorder, recurrent, mild correlating with TSH & Free in Major depressive disorder, recurrent, mild (F33.0: T4 Rule-Out) deviation outside TSH 0.8 – 2.5 mIU/L (F33.0)
- • Functional depression & mood impact requiring medication response pharmacogenomics [Major depressive disorder, recurrent, mild F33.0] evaluation (F33.0)
Major depressive disorder, recurrent, mild Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | F33.0 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Depression, Bipolar & Mood Disorders | NLM Clinical Tables |
| Diagnostic / Lab Marker: TSH & Free in Major depressive disorder, recurrent, mild (F33.0: T4 Rule-Out) | TSH 0.8 – 2.5 mIU/L (F33.0) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Serum Vitamin D in Major depressive disorder, recurrent, mild (F33.0: & RBC Folate) | 25(OH)D 40 – 65 ng/mL (F33.0) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: PHQ-9 Symptom Severity in Major depressive disorder, recurrent, mild (F33.0: Score) | < 4 (clinical remission) (F33.0) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Major depressive disorder, recurrent, mild
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Zopapogene Imadenovec Papzimeos • RxCUI 2723367 | FDA Prescription Therapeutic Agent | 85% | $0.2500 | $ 18.63 /mo |
| Avutometinib Potassium and Defactinib Hydrochloride Avutometinib Potassium and Defactinib Hydrochloride Generic • RxCUI 2714507 | FDA Prescription Therapeutic Agent | 81% | $2.5800 | $ 112.99 /mo |
| Hemin Panhematin • RxCUI 1926452 | FDA Prescription Therapeutic Agent | 81% | $1.0300 | $ 50.22 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Major depressive disorder, recurrent, mild)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Meta-Analysis: Dose-Response Relationship of Selective Serotonin Reuptake: What a 10,039-Participant Study Found Higher doses of SSRIs appear slightly more effective in depression. The American journal of psychiatry • 2016-02-01 • Meta-Analysis | N = 10,039 | 99/100 | PMID 26552940 ↗ |
| New Insights on Pharmacological and non-pharmacological treatments for depression in: What a 10,991-Participant Study Found Herbal medicine and mirtazapine had no significant difference in overall risk of side effects compared with placebo. Psychiatry research • 2019-11-15 • Meta-Analysis | N = 10,991 | 99/100 | PMID 31627074 ↗ |
| New Insights on Antidepressants for the treatment of adults with depression in the maintenance: What a 9,384-Participant Study Found Compared to placebo, venlafaxine was associated with a lower incidence of dizziness, while desvenlafaxine, sertraline, and vortioxetine were associated with a higher incidence of nausea/vomiting. Molecular psychiatry • 2023-01-15 • Meta-Analysis | N = 9,384 | 99/100 | PMID 36253442 ↗ |
| New Insights on Modeling the efficacy of a novel antidepressant zuranolone for: What a 8,735-Participant Study Found Primary side effects related to zuranolone included somnolence, headache, dizziness, and sedation, with no severe safety signals observed. Journal of affective disorders • 2026-01-01 • Meta-Analysis | N = 8,735 | 99/100 | PMID 40876640 ↗ |
| New Insights on Major outcomes in high-risk hypertensive patients randomized to: What a 9,048-Participant Study Found Thiazide-type diuretics are superior in preventing 1 or more major forms of CVD and are less expensive. JAMA • 2002-12-18 • Randomized Controlled Trial | N = 9,048 | 96/100 | PMID 12479763 ↗ |
Major depressive disorder, recurrent, mild Patient Community & “People Like Me” Threads
Filter Major depressive disorder, recurrent, mild community threads and patient logs by age, biological sex, dosage, and treatment duration.